Biomaterial Database

Dissolution test method for rifampicin-isoniazid fixed dose formulations. 1994

K C Jindal, and R S Chaudhary, and A K Singla, and S S Gangwal, and S Khanna

Lupin Laboratories Limited, M.I.D.C., Aurangabad, India.

A dissolution procedure for a rifampicin-isoniazid combination formulation was evaluated using 0.1 N hydrochloric acid solution and 0.4% (w/v) sodium lauryl sulphate solution as dissolution media. Rifampicin and isoniazid along with degradation components were chromatographed using reversed-phase liquid chromatography on a 10 microns octadecylsilica column using methanol-0.01 M disodium hydrogen phosphate (70:30, v/v; pH 4.6 +/- 0.1) as mobile phase. The detection was carried out at 254 nm. The data obtained indicate that the dissolution medium consisting of 0.4% (w/v) sodium lauryl sulphate solution is suitable for such a combination. The degradation observed in dissolution medium consisting of 0.1 N hydrochloric acid was 10-23%.

UI	MeSH Term	Description	Entries
D007202	Indicators and Reagents	Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant & Hackh's Chemical Dictionary, 5th ed, p301, p499)	Indicator,Reagent,Reagents,Indicators,Reagents and Indicators
D007538	Isoniazid	Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.	Isonicotinic Acid Hydrazide,Ftivazide,Isonex,Isonicotinic Acid Vanillylidenehydrazide,Phthivazid,Phthivazide,Tubazide,Acid Vanillylidenehydrazide, Isonicotinic,Hydrazide, Isonicotinic Acid,Vanillylidenehydrazide, Isonicotinic Acid
D002214	Capsules	Hard or soft soluble containers used for the oral administration of medicine.	Capsule,Microcapsule,Microcapsules
D002851	Chromatography, High Pressure Liquid	Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed.	Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D004338	Drug Combinations	Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture.	Drug Combination,Combination, Drug,Combinations, Drug
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012293	Rifampin	A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)	Rifampicin,Benemycin,Rifadin,Rimactan,Rimactane,Tubocin
D012995	Solubility	The ability of a substance to be dissolved, i.e. to form a solution with another substance. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed)	Solubilities
D013056	Spectrophotometry, Ultraviolet	Determination of the spectra of ultraviolet absorption by specific molecules in gases or liquids, for example Cl2, SO2, NO2, CS2, ozone, mercury vapor, and various unsaturated compounds. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)	Ultraviolet Spectrophotometry

Related Publications

K C Jindal, and R S Chaudhary, and A K Singla, and S S Gangwal, and S Khanna

Dissolution test as a surrogate for quality evaluation of rifampicin containing fixed dose combination formulations.

December 2004, International journal of pharmaceutics,

K C Jindal, and R S Chaudhary, and A K Singla, and S S Gangwal, and S Khanna

Bioequivalence study of rifampicin in fixed-dose combination of rifampicin and isoniazid vs. separate formulations.

November 1999, Methods and findings in experimental and clinical pharmacology,

K C Jindal, and R S Chaudhary, and A K Singla, and S S Gangwal, and S Khanna

Comparative bioavailability of rifampicin and isoniazid in fixed-dose combinations and single-drug formulations.

December 2014, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease,

K C Jindal, and R S Chaudhary, and A K Singla, and S S Gangwal, and S Khanna

Bioequivalence assessment of rifampicin, isoniazid and pyrazinamide in a fixed dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol vs. separate formulations.

October 2002, International journal of clinical pharmacology and therapeutics,

K C Jindal, and R S Chaudhary, and A K Singla, and S S Gangwal, and S Khanna

Bioavailability of rifampicin, isoniazid and pyrazinamide from fixed-dose combination capsules.

October 1998, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease,

K C Jindal, and R S Chaudhary, and A K Singla, and S S Gangwal, and S Khanna

Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.

May 2004, International journal of pharmaceutics,

K C Jindal, and R S Chaudhary, and A K Singla, and S S Gangwal, and S Khanna

Isoniazid, pyrazinamide and rifampicin content variation in split fixed-dose combination tablets.

January 2014, PloS one,

K C Jindal, and R S Chaudhary, and A K Singla, and S S Gangwal, and S Khanna

Assessment of bioequivalence of rifampicin, isoniazid and pyrazinamide in a four drug fixed dose combination with separate formulations at the same dose levels.

February 2002, International journal of pharmaceutics,

K C Jindal, and R S Chaudhary, and A K Singla, and S S Gangwal, and S Khanna

Dissolution testing of marketed rifampicin containing fixed dose combination formulations using a new discriminative media: a post marketing retrospective study.

October 2006, Die Pharmazie,